source
- Sionna Therapeutics cuts 46% of staff after cystic fibrosis trial missSionna Therapeutics announced it will lay off roughly half of its employees as it reassesses its strategy following a recent setback in its cystic fibrosis program. The company’s lead candidate, S…
- Connect Biopharma's asthma drug rademikibart misses primary endpoint in Phase 2 trialConnect Biopharma reported that its IL-4/IL-13 blocker rademikibart failed to meet the primary endpoint in a Phase 2 study in asthma patients with type-2 inflammation. The trial enrolled 160 patie…